Figure 6 | Scientific Reports

Figure 6

From: Assessment and Clinical Relevance of Serum IL-19 Levels in Psoriasis and Atopic Dermatitis Using a Sensitive and Specific Novel Immunoassay

Figure 6The alternative text for this image may have been generated using AI.

Etanercept decreases circulating IL-19 concentrations in psoriasis patients, but decreases are not as rapid or robust as those observed with ixekizumab. (a) Samples were collected from psoriasis patients enrolled in a phase 3 ixekizumab study (UNCOVER-2, NCT01597245), which included an etanercept active comparator arm16. Circulating IL-19 was measured at baseline and after 12 weeks of treatment with the TNFα inhibitor etanercept in 163 patients with psoriasis. All data from baseline and after 12 weeks of treatment are shown. Collectively, serum IL-19 results were highly correlated with PASI (Spearman’s r = 0.60, p < 0.0001). (b) Overlaid histograms were prepared for end-of-induction (week 12) PASI scores for etanercept (ETN) (purple, n = 334, all etanercept patients; 36% of all etanercept patients were sPGA = 0, 1 responders) and ixekizumab (IXE) induction responders who were randomized to placebo and then re-administered ixekizumab upon relapse (blue, n = 94 out of 341 patients initially treated with ixekizumab; 83% of all ixekizumab patients were sPGA = 0, 1 responders). (c) Serum IL-19 levels in psoriasis patients were measured at baseline and during 12 weeks of treatment with etanercept (ETN) or ixekizumab (IXE). Data from 164 etanercept patients, 31 ixekizumab responder patients, and 35 of the best-responding etanercept patients (matched for ixekizumab response), were plotted as least square means ± standard error of the mean estimated from a mixed effects model using an unstructured covariance matrix. Model fitting was performed using log10 transformed IL-19 concentrations. The dashed horizontal line indicates the upper limit of normal (21 pg/mL). Comparisons between etanercept patients and ixekizumab patients at weeks 1, 4, and 12 were all statistically significant (p < 0.0001). (d) Serum IL-19 levels after 4 weeks (top) or 12 weeks (bottom) of etanercept treatment are plotted versus PASI at 12 weeks for 164 etanercept patients matched to the overall etanercept PASI distribution. The dashed horizontal line indicates the upper limit of normal. Lower IL-19 levels after treatment with etanercept for 4 weeks or 12 weeks were correlated with improved PASI response at 12 weeks. Top panel one-way ANOVA (p < 0.0001). Bottom panel one-way ANOVA (p < 0.0001).

Back to article page